AbbVie’s $906M Psychedelic Bet: What It Means for Psychedelic Medicine
The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...
The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...
Global pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, in what would become ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
